The overarching goal of the SFP Coalition’s multi-annual work programme is to improve the health of EU citizens and reduce health inequalities by promoting smoking prevention at EU and Member State level with a special focus on measures that prevent the uptake of smoking by young people.
The work plan for 2017 will conclude the 3-year cycle of activities planned in the FPA 2015-2017 while preparing the ground for a new cycle of activities. In 2017 the main priorities will be to coordinate the civil society response to the Tobacco Tax Directive review, to promote tobacco control policy research on the political agenda, and to continue exposing and countering tobacco industry interference in policy making across all tobacco control policy areas .



Thalassaemia, a previously fatal childhood genetic disease, can today be effectively prevented and appropriately treated, as a result of medical and scientific advances in the last three decades. However, thalassaemia’s prioritisation on national health agendas and the development of national plans for its effective control in the EU has been hampered by the many challenges involved, mainly related to its rarity and migration.

THALassaemia In Action 2018 (THALIA2018) focuses on Europe, targeting patients with thalassaemia and other haemoglobinopathies, healthcare professionals and policymakers and aims to attain four general objectives, based on TIF’s main pillars of activities:

1. Continue and strengthen the education of patients/parents and healthcare professionals, as well as the patients’ capacity, competency and networking within and across countries and regions of Europe. This is to be achieved via the development of e-learning tools and the launching of capacity building courses and training seminars.

2. Raise awareness on thalassaemia and the importance of optimal care amongst the public at large, as well as among THALIA target groups at national and European level. This will be attained using an array of online tools, activities and publications.

3. Prioritise haemoglobin disorders and their control (prevention and management) at European level. This will be accomplished by establishing and training national patients’ associations in EU priority countries, creating an EU Electronic Health Record and entering into policy dialogue with policymakers at national and European level.

4. Support research programmes and studies focused on the clinical management of Thalassaemia. This is to be achieved via the publication of guidelines on the clinical management of Thalassaemia, participating in scientific conferences and providing medical specialists in priority countries with fellowships.

Knowledge is our power.


The Correlation Network (CN) is a European civil society network and centre of expertise in the field of drug use, harm reduction and social inclusion.

Overall objective of this proposal:
Improve the access to and the quality of harm reduction services for People Who Use Drugs (PWUD), including other related vulnerable and marginalised people and to enhance policies and practices that increase social inclusion.

This is achieved by the following strategic objectives
- Strengthen the network and the collaboration with its members and partners through an adequate and solid organisational network structure
- Monitor developments and collect information and evidence in the field of drug use and harm reduction, by involving the expertise of civil society organisations
- Strengthen capacities of the various players in the field of drug use and harm reduction and facilitate exchange between network members and partners
- Advocate for full coverage of harm reduction programmes in Europe, addressing both health and social aspects.

All CN activities will pay specific attention to Hepatitis C, new drug trends and drug patterns and overdose prevention.

Relevant CN outputs include : Sustainable network, Annual Monitoring Reports, Online knowledge and training hub, European Harm Reduction Conferences (2018/20), policy recommendations.

CN contributes to the Third Health Programme (THP) by promoting health (in particular harm reduction), prevent diseases (in particular drug-related diseases and infectious diseases such as HCV and HIV/AIDS), and foster supportive environments for healthy lifestyles (e.g. by reducing barriers to access health and social services).

CN contributes as well to the following THP priorities:
1.2. Drugs-related health damage, including information and prevention
1.3. HIV/AIDS, tuberculosis and hepatitis
2.2. Capacity-building against health threats in Member States, including, where appropriate, cooperation with neighbouring countries.


The European Public Health Association (EUPHA) is a major player in the European public health area. Since our establishment in 1992, EUPHA has been growing and has an increasing influence on the public health dialogue in Europe.
EUPHA will continue her activities in 2018, fully in line with the 3rd Health Programme of the European Commission. In order to be a leading actor in the public health arena in Europe, we will be introducing a number of new initiatives made possible through the additional funding of the 2018 operating grant. EUPHA identifies the following operational targets for 2018:
1. Strengthening national public health associations;
2. Advocating for public health on the European agenda;
3. Representing the European voice at global level and supporting public health at global level;
4. Providing actively and accurately the evidence to make informed practice and policy decisions in the field of public health;
5. Nurturing the expertise and knowledge on specific public health topics;
6. Preparing the future generation of public health professionals for their leadership role in public health.
EUPHA’s strong organisation, with 25 years of experience, is a solid basis to contribute to the objectives of the Third Health Programme and to play a key role in the European public health area.



Under its leading title of the FPA 2018 - 2021, Stronger Together, AIDS Action Europe (AAE) will implement its work programme in 2018. As a comprehensive NGO network of 415 NGOs, national networks, AIDS service organisations, and community based groups in 47 countries in the WHO European Region, AAE is a unique player with substantial added value for European policy making and programme implementation in the response to HIV/AIDS, TB and hepatitis.
Considering the epidemiological background of the three diseases and after consulting AAE Members and partners, the following six core thematic areas were identified to focus on in the upcoming four years:
Community based voluntary counselling and testing (CBVCT)
Affordability and accessibility to medicines
Tackling legal barriers in the response to HIV, TB and hepatitis
Criminalisation of HIV non-disclosure, exposure and transmission
Sexual and reproductive health and rights (SRHR)
Tackling stigma and discrimination
The three main objectives of the work are
1.AAE contributes effectively to the HIV, TB and hepatitis response in Europe
2.AAE provides platforms to communicate and facilitate collaboration, networking, and linking and learning
3.Continuous improvement of network collaboration through governance and internal management.
Within Objective I, AAE will serve as the secretariat to the EU CSF, monitor and contribute to policy developments, coordinate the European HIV Legal Forum, and advocate for CS concerns. Objective 2 comprises improved bilingual communication and exchange, intensified social media communication, dissemination of 3rd health programme information and tools, support of national and regional affordability advocacy efforts and provision of capacity building activities. Eventually, objective III includes ensuring topic-related sub-network cooperation, overall governance by the AAE Steering Committee and implementation, monitoring, evaluation, follow-up and fundraising for the work programme.
